PMID- 27550819
OWN - NLM
STAT- MEDLINE
DCOM- 20170529
LR  - 20230607
IS  - 1474-1768 (Electronic)
IS  - 1474-175X (Print)
IS  - 1474-175X (Linking)
VI  - 16
IP  - 9
DP  - 2016 Aug 23
TI  - Engineered T cells: the promise and challenges of cancer immunotherapy.
PG  - 566-81
LID - 10.1038/nrc.2016.97 [doi]
AB  - The immune system evolved to distinguish non-self from self to protect the 
      organism. As cancer is derived from our own cells, immune responses to 
      dysregulated cell growth present a unique challenge. This is compounded by 
      mechanisms of immune evasion and immunosuppression that develop in the tumour 
      microenvironment. The modern genetic toolbox enables the adoptive transfer of 
      engineered T cells to create enhanced anticancer immune functions where natural 
      cancer-specific immune responses have failed. Genetically engineered T cells, 
      so-called 'living drugs', represent a new paradigm in anticancer therapy. Recent 
      clinical trials using T cells engineered to express chimeric antigen receptors 
      (CARs) or engineered T cell receptors (TCRs) have produced stunning results in 
      patients with relapsed or refractory haematological malignancies. In this Review 
      we describe some of the most recent and promising advances in engineered T cell 
      therapy with a particular emphasis on what the next generation of T cell therapy 
      is likely to entail.
FAU - Fesnak, Andrew D
AU  - Fesnak AD
AD  - Department of Pathology and Laboratory Medicine and Center for Cellular 
      Immunotherapies, Perelman School of Medicine, University of Pennsylvania, 
      Philadelphia, Pennsylvania 19104-5156, USA.
FAU - June, Carl H
AU  - June CH
AD  - Department of Pathology and Laboratory Medicine and Center for Cellular 
      Immunotherapies, Perelman School of Medicine, University of Pennsylvania, 
      Philadelphia, Pennsylvania 19104-5156, USA.
FAU - Levine, Bruce L
AU  - Levine BL
AD  - Department of Pathology and Laboratory Medicine and Center for Cellular 
      Immunotherapies, Perelman School of Medicine, University of Pennsylvania, 
      Philadelphia, Pennsylvania 19104-5156, USA.
LA  - eng
GR  - P30 CA016520/CA/NCI NIH HHS/United States
GR  - R01 CA120409/CA/NCI NIH HHS/United States
GR  - R01 CA165206/CA/NCI NIH HHS/United States
GR  - T32 HL007775/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - England
TA  - Nat Rev Cancer
JT  - Nature reviews. Cancer
JID - 101124168
RN  - 0 (Antigens, CD19)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (CD19 molecule, human)
RN  - 0 (Costimulatory and Inhibitory T-Cell Receptors)
RN  - 0 (Cytokines)
RN  - 0 (HLA Antigens)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Recombinant Fusion Proteins)
SB  - IM
MH  - Antigen Presentation
MH  - Antigens, CD19/immunology
MH  - Antigens, Neoplasm/immunology
MH  - Clinical Trials as Topic
MH  - Costimulatory and Inhibitory T-Cell Receptors/genetics/immunology
MH  - Cytokines/metabolism
MH  - Forecasting
MH  - Gene Editing
MH  - Gene Transfer Techniques
MH  - Genetic Engineering
MH  - HLA Antigens/immunology
MH  - Hematologic Neoplasms/immunology/therapy
MH  - Humans
MH  - Immunotherapy, Adoptive/adverse effects/*methods/trends
MH  - Models, Immunological
MH  - Neoplasms/immunology/*therapy
MH  - Receptors, Antigen, T-Cell/genetics/*immunology
MH  - Recombinant Fusion Proteins/genetics/immunology
MH  - Syndrome
MH  - T-Cell Antigen Receptor Specificity
MH  - T-Lymphocyte Subsets/*immunology/transplantation
MH  - Tumor Escape
MH  - Tumor Microenvironment/immunology
PMC - PMC5543811
MID - NIHMS855771
EDAT- 2016/08/24 06:00
MHDA- 2017/05/30 06:00
PMCR- 2017/08/23
CRDT- 2016/08/24 06:00
PHST- 2016/08/24 06:00 [entrez]
PHST- 2016/08/24 06:00 [pubmed]
PHST- 2017/05/30 06:00 [medline]
PHST- 2017/08/23 00:00 [pmc-release]
AID - nrc.2016.97 [pii]
AID - 10.1038/nrc.2016.97 [doi]
PST - ppublish
SO  - Nat Rev Cancer. 2016 Aug 23;16(9):566-81. doi: 10.1038/nrc.2016.97.